Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med.2016;375:1834– 1844. 4. Marso SP, Daniels GH, Brown-Frandsen K, et al. LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311 – 322. 5. Ahrén B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5:341– 354. 6. Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once- weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo- controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol.2017;5:251– 260. 7. Davies M, Pieber TR, Artoft-Nielsen ML, et al. Effect of oral semaglu- tide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: A randomized clinical trial. JAMA.2017;318(15):1460– 1470.  This phase 2 randomized clinical trial is the first clinical study to confirm that oral semaglutide resulted in improved glycemic control and reduced body weight compared with placebo. 8. Buckley ST, Schéele SG, Kirk RK, et al. Mechanism of absorption mediated by SNAC in an oral formulation of semaglutide. Diabetes. 2017;66(Suppl 1):1206– P.  In vitro data demonstrate that SNAC promotes absorption of semaglutide across gastric mucosa in a concentration-depen- dent manner via effects on transcellular pathways and that the absorption-enhancing effect of SNAC is both transient and fully reversible. 9. Connor A, Borregaard J, Buckley ST, et al. 
